The present work investigated the behavior of smokers after resection of non-small cell lung cancer (NSCLC) in stages IB-IIIA. This is a phase III study that also evaluated the role of adjuvant therapy for this group. “Unfortunately, the use of bevacizumab associated with platinum-based chemotherapy did not lead to an increase in overall survival in patients diagnosed with early-stage NSCLC who underwent surgical resection,” commented Flavia Amaral Duarte, clinical oncologist at Oncocentro BH and Oncobio. Luiz Flavio Coutinho and Breno Bastos, oncologists at Oncocentro BH, agree that “the study was unable to prove the efficacy of bevacizumab in this patient population, making it clear that the most important factor for the main outcome of overall survival is the patient’s smoking habit during the treatment”.
Grupo Oncoclínicas recently launched a smoking cessation program, starting in Belo Horizonte: “The program is fundamental for the prevention and treatment of smoking. All smokers should be referred to cessation programs, including those without diseases, such as patients in cancer screening protocols”, commented Luiz Fernando Ferreira Pereira, pulmonologist at Oncobio and organizer of the Smoking Cessation Program at Grupo Oncoclínicas.
Visit our website, read the full article and also learn about the Oncoclínicas Group’s Smoking Cessation Program.